[Federal Register Volume 60, Number 196 (Wednesday, October 11, 1995)]
[Notices]
[Pages 52918-52919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-25082]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
Licensing Specialist at the Office of Technology Transfer, 

[[Page 52919]]
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804 (telephone 301/496-7735; fax 301/402-
0220). A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

Method and Use of Trichohyalin and Transglutaminase-3

Steinert, P.M., Lee, S-C, Kim, I-G (NIAMS)
Filed 30 Apr 93
Serial No. 08/056,200
Licensing Contact: Carol Lavrich, 301/496-7735 ext 287

    The invention relates to the discovery of the sequence of a protein 
involved in forming a structural component of the hair follicle and 
epidermis: human trichohyalin. Human trichohyalin is an ideal substrate 
for cross-linking to other proteins, a reaction that is catalyzed by 
transglutaminase-3. Trichohyalin used in conjunction with 
transglutaminase forms a naturally-occurring proteinaceous gel with 
potential application in the areas of food production/stabilization, 
cosmetics and coverage for open wounds and burns. We have demonstrated 
that, using cloned cDNAs, the combination of human trichohyalin with an 
enzyme that is capable of cross-linking proteins can produce a stable, 
quickly-formed proteinaceous gel. This technology may be useful for the 
treatment of skin diseases and may have benefit as a transglutaminase 
replacement therapy.
    The goal is to use the resources of a collaborator to further 
develop the manufacturing and purification process to increase yield, 
to conduct toxicology studies, and to evaluate potential use and 
efficacy of the compound. It is expected that the collaborator will 
have the resources, facilities, and capabilities to produce the 
compound in sufficient quantity and conduct testing of the concepts. 
[portfolio: Internal Medicine--Miscellaneous]

A New and Distinctive DNA Sequence of E. Coli 0157:H7 and Its Uses for 
Rapid, Sensitive, and Specific Detection of 0157:H7 and Other 
Enterohemorrhagic E. Coli

Hall, R.H. and Xu, J-G. (FDA)
Filed 14 Jun 94
Serial No. 08/258,188
Licensing Contact: Girish Barua, 301/496-7735 ext 263

    The invention provides isolated nucleic acid sequences 
corresponding to the EHEC hlyA gene, the EHEC hlyB gene, and the 
intergenic region between the hlyA gene and the hlyB gene which are 
unique to enterohemorrhagic E. coli. It also covers the methods for 
detecting 0157:H7 and other enterohemorrhagic E. coli by targeting the 
EHEC hlyA gene, the hlyB gene, fragments and combinations thereof. Such 
methods rely on nucleic acid probes and amplification primers specific 
for sequences of hlyA and hlyB genes. As such, the technology covered 
in the invention provides nucleic acid probes and amplification primers 
useful for the rapid, sensitive, and specific amplification for 
detection of enterohemorrhagic E. coli and a detection kit embracing 
the above aspects. [portfolio: Infectious Diseases--Diagnostics, 
bacterial]

Chimeric Papillomavirus-Like Particles

Lowy, D.R., Schiller, J.T., Greenstone, H. (NCI)
Filed 6 Oct 94
Serial No. 08/319,467
Licensing Contact: Steven Ferguson, 301/496-7735 ext 266

    Human papillomavirus (HPV) infection causes benign epithelial and 
fibro-epithelial tumors (genital warts), and is implicated as a cause 
of certain forms of cancer, particularly cervical cancer.
    The current invention embodies an improved vaccine against 
infection by papillomaviruses. Two viral genes, L1 and L2, encode the 
proteins which give rise to papillomavirus particles. The vaccine 
embodied herein consists of recombinant papilloma virus-like particles 
(VLPs), which are chimeras comprised of the L1 capsid protein and an L2 
fusion product. The fusion product consists of the L2 capsid protein 
recombinantly fused to other HPV peptides or proteins. The resulting 
VLPs exhibit the ability to induce high levels of neutralizing 
antibodies against papillomavirus infection. The resulting subunit 
vaccine is believed to demonstrate improved efficacy in preventing HPV 
infection, compared to VLPs composed of L1 and L2 proteins alone, and 
may also prove valuable as a therapeutic agent in eliminating pre-
existing HPV infection.
    In addition, the L2 fusion products can incorporate peptides or 
proteins of other infectious agents, resulting in VLPs which can 
immunize recipients against not only HPV infection, but also other, 
unrelated diseases. [portfolio: Infectious Diseases--Diagnostics, 
viral, non-AIDS; Infectious Diseases--Vaccines, viral, non-AIDS]

Chiral Separation of Enantiomers by High-Speed Countercurrent 
Chromatography

Ma, Y., Ito, Y. (NHLBI)
Filed 16 Dec 94
Serial No. 08/357,845
Licensing Contact: David Sadowski, 301/496-7735 ext 288

    The preparation of optically active compounds is very important for 
the development of new biologically active substances. The ability to 
separate enantiomers is therefore crucial. This invention embodies a 
chromatographic technique that allows for gram-quantity separation of 
chiral compounds. This method provides unique advantages over 
conventional methods in terms of sample size, choice of chiral 
selectors, and cost-effectiveness. [portfolio: Devices/
Instrumentation--Research Tools]

    Dated: September 29, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-25082 Filed 10-10-95; 8:45 am]
BILLING CODE 4140-01-P